Clinical Trial Update: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder [Phase 3]

View source ↗

Summary

Open-label, flexible-dose study to evaluate the long-term safety and tolerability of cariprazine in pediatric participants with schizophrenia, bipolar I disorde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder
• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• cariprazine (cariprazine)

Snippet

Sponsor: AbbVie | Conditions: Schizophrenia, Bipolar I Disorder | Phase 3 | Status: COMPLETED